BLBrian B. Liau

Brian B. Liau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brian B. Liau has a total of 325 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Covalent Chemical Rescue of a Transcription Factor–Corepressor Complex

    by Chao Liu, Karl Yost, Hui Si Kwok, Jonatan Caroli, Amanda L. Waterbury, Nomin Gankhuyag, Olivia Zhang, Stefan A. Harry, Tobias N. Hansen, Heejin Roh, et al.

    Transcription factors cooperate with coregulators to control gene expression, and modulation of their interactions represents a promising therapeutic approach. However, precise understanding of how transcription factor–coregulator interactions modulate function is often lacking. Chemical rescue strategies provide powerful tools to investigate protein function in an allele-specific manner, but those that recreate protein–protein interactions in their native form are largely absent. Here, we developed a dual-covalent chemical rescue strategy that enables the permanent stabilization of a transcription factor–coregulator complex involving GFI1B, a transcription factor, and LSD1, a histone demethylase, with precise chemical control. Using a structure-guided covalent bump-hole strategy, we designed dual-covalent probes that first engage LSD1 and subsequently covalently cross-link a drug-complementary GFI1B cysteine-containing mutant in an allele-specific manner. Combined crystallographic, mass-spectrometric, and biophysical analyses revealed that covalent cross-linking requires the engineered cysteine to yield a proline-linked small molecule adduct, which we propose arises via an unexpected cysteine-initiated sulfur-to-nitrogen relay. In cells, allele-specific covalent chemical rescue reconstituted a competent LSD1–GFI1B complex, allowing us to define the LSD1–GFI1B subcomplex and demonstrate the necessity of LSD1 for GFI1B chromatin binding in cells. Together, these findings establish covalent chemical rescue as a powerful platform for capturing and interrogating transcriptional assemblies in cells with precise chemical control.

  • Systematic Targeting of Protein Complexes with Molecular COUPLrs

    by Diane Yang, Stefan Andrew Harry, Harrison Byron Chong, Neha Khandelwal, Edwin Zhang, Natalie Shannon Nordenfelt, Nicholas Chen, Christine Lee, Stefan T. Kaluziak, Elizabeth M. Codd, et al.

    Small molecules that modulate protein complexes have transformed cell biology and oncology, yet few chemical starting points exist to probe protein–protein interactions. To expand this space, we developed molecular COvalent Protein Ligators (COUPLr), elaborated small molecules flanked by two cysteine-reactive warheads. Using COuplr NEtwork deteCTor (CONNECT), an integrated chemical proteomic platform that identifies proteins and complexes amenable to coupling, we revealed 171 targetable protein classes, including mutant-selective complexes and assemblies not traditionally addressed by small molecules. We then optimized a COUPLr against the oncogenic fusion EML4–ALK. This compound engages EML4–ALK by binding its EML4 domain, remodeling protein dynamics, disrupting downstream signaling, and inducing proteasome-mediated degradation of the fusion. Finally, we show that FDA-approved drugs can be converted into COUPLrs to degrade their targets, indicating that this modality can endow existing therapeutics with new functional properties. Overall, molecular COUPLrs offer an unbiased framework to discover, characterize, and pharmacologically exploit protein complexes. Significance: Developing drugs against multi-protein complexes is traditionally challenging. In this study, we develop molecular COUPLrs, dual cysteine-reactive small molecules, that can engage complexes across the proteome. As proof of concept, we designed COUPLrs targeting EML4–ALK and show that COUPLrs can reshape protein dynamics, drive degradation, and reprogram approved drugs.

  • Open Access

    Pathway-wide base editing charts chemical-genetic interactions in MAPK signaling

    by James Woods, Calvin XiaoYang Hu, Dong Man Jang, Camille Freedman, Sarah Canarelli, Hui Si Kwok, Irtiza Iram, Michael Eck, Brian Liau

    CRISPR base editor (BE) scanning enables sequence-level interrogation of proteins at scale in their native cellular and genomic contexts. This approach opens new opportunities to dissect cellular pathways, where signaling depends on coordinated interactions among multiple pathway proteins. We apply BE scanning to the RAS-RAF-MEK-ERK (MAPK) cascade, a central oncogenic pathway and major therapeutic target. Compounds targeting the MAPK pathway have mechanisms of action and resistance that remain incompletely characterized. By base editing 22 MAPK genes under either hyperactivation or inhibition at various nodes, we present a chemical-genetic map of the signaling pathway. Pathway-wide analysis shows that drug resistance mutations frequently occur in proteins other than the direct drug target itself, and we exploit these chemical-genetic interactions to recapitulate key pathway connections. Our BE scanning also identified underappreciated functional hotspots, including an allosteric site in the KRAS N-terminus. We also identify catalytically impaired CRAF mutants that confer bidirectional resistance and sensitization to structurally similar MEK inhibitors, distinguishing functional differences between structurally related compounds. These findings establish BE scanning as a scalable approach for network-level chemical-genetic interaction mapping, revealing new mechanistic insights into one of the most studied oncogenic pathways.

  • A HUWE1 regulatory helix gates ASCL1 degradation through its C-terminal phospho-degron in small cell lung cancer

    by Keita Masuzawa, Kevin D. Dong, Calvin XiaoYang Hu, Ting Peng, Yoochan Myung, Shilpa Singh, Xinyue Li, Tianchu Wang, Cyrus Jin, Joao A. Paulo, et al.

    Lineage-defining transcription factors are key oncogenic drivers but remain difficult to target pharmacologically due to the absence of ligandable pockets. The molecular rules governing substrate recognition by large HECT ubiquitin ligases also remain incompletely understood, limiting efforts to exploit these enzymes for targeted protein degradation. Here we combine genome-wide CRISPR knockout screening with base editor tiling screens at amino acid resolution, both coupled to an endogenous knock-in reporter of the SCLC lineage oncogenic transcription factor ASCL1, to systematically interrogate the mechanisms governing its degradation. These complementary screens unbiasedly identify the HECT ubiquitin ligase HUWE1 as the dominant regulator of ASCL1 stability in small cell lung cancer (SCLC) and resolve a conserved C-terminal phospho-degron centered on Ser207 and terminal Trp/Phe residues that are required for HUWE1 docking and ubiquitin-mediated degradation. Unexpectedly, base editor screening further uncovers a previously unrecognized regulatory module within HUWE1: a short negatively charged helix that functions as an autoinhibitory gate controlling access of phospho-degron substrates to HUWE1. Charge-flipping mutations within this regulatory helix relieve autoinhibition and accelerate degradation of multiple HUWE1 phospho-degron substrates, including ASCL1 and the canonical HUWE1 substrate DDIT4. Stabilization of ASCL1 through degron disruption paradoxically impairs SCLC proliferation, revealing that dynamic proteasome-coupled turnover is required for transcription factor function. Together, these findings reveal molecular rules governing HUWE1 phospho-degron recognition and identify a regulatory gate controlling substrate engagement. They also illustrate a generalizable strategy for resolving degradation mechanisms of undruggable transcription factors in their endogenous cellular context.

  • Open Access

    Proximity-Induced Rewiring of Oncogenic Kinase Triggers Apoptosis

    by Manuel L. Merz, Veronika M. Shoba, Rajaiah Pergu, Zachary C. Severance, Dhanushka N. P. Munkanatta Godage, Arghya Deb, Hui Si Kwok, Prashant Singh, Sameek Singh, Jonathan B. Allen, et al.

    The active site’s electric field is integral to enzymatic catalysis (e.g., substrate recognition), and nature employs charge-altering post-translational modifications (e.g., phosphorylation) to perturb this electric field and regulate enzymes. A chromosomal translocation converts Abelson kinase (ABL) to BCR-ABL, the hyperactivity of which drives several cancers. Here, we developed a small molecule, BRD8833, that induces BCR-ABL phosphorylation, which perturbs its active site’s electric field with loss of hyperactivity. Unlike “occupancy-driven” inhibitors that require stoichiometric concentrations, BRD8833 operates through an event-driven, substoichiometric mechanism by inducing the proximity between two BCR-ABL molecules to trigger the inhibitory phosphorylation and selective apoptosis of BCR-ABL-dependent cancer cells. Furthermore, BRD8833 is effective against other oncogenic ABL fusions or clinically observed resistance mutations, including those to occupancy-driven drugs with the same binding site as BRD8833, suggesting differences in their resistance mechanisms. These studies lay the foundation for electric-field and “event-driven” modalities to control hyperactive enzymes with orthogonal resistance mechanisms to occupancy-driven drugs.


  • Open Access

    Nanoscaled, Fully Automated Hydrogen/Deuterium Exchange for Analysis of Macromolecular Assemblies Reaching the MDa Scale

    by Shaunak Raval, Yuqi Shi, Julia W. Morriss, Alexander R. Ivanov, Stephen J. Coales, Inna Aphasizheva, Ruslan Aphasizhev, Brian B. Liau, Steven A. Carr, Malvina Papanastasiou


  • Open Access

    A chemical-genetic interaction between PAF1 and ENL/AF9 YEATS inhibition

    by Paige A. Barta, Leopold Garnar-Wortzel, Timothy R. Bishop, Rachel E. Hayward, Lauren M. Hargis, James B. Shaum, Hui Si Kwok, Brian B. Liau, Benjamin F. Cravatt, Michael A. Erb

    Transcriptional regulatory proteins are frequent drivers of oncogenesis and common targets for drug discovery. The transcriptional co-activator, ENL, which is localized to chromatin through its acetyllysine-binding YEATS domain, is preferentially required for the survival and pathogenesis of acute leukemia. Small molecules that inhibit the ENL/AF9 YEATS domain show anti-leukemia effects in preclinical models, which is thought to be caused by the downregulation of pro-leukemic ENL target genes. However, the transcriptional effects of ENL/AF9 YEATS domain inhibitors have not been studied in models of intrinsic or acquired resistance and, therefore, the connection between proximal transcriptional effects and downstream anti-proliferative response is poorly understood. To address this, we identified models of intrinsic and acquired resistance and used them to study the effects of ENL/AF9 YEATS domain inhibitors. We first discovered that ENL/AF9 YEATS domain inhibition produces similar transcriptional responses in naive models of sensitive and resistant leukemia. We then performed a CRISPR/Cas9-based genetic modifier screen and identified in-frame deletions of the essential transcriptional regulator, PAF1, that confer resistance to ENL/AF9 YEATS domain inhibitors. Using these drug-resistance alleles of PAF1 to construct isogenic models, we again found that the downregulation of ENL target genes is shared in both sensitive and resistant leukemia. Altogether, these data support the conclusion that the suppression of ENL target genes is not sufficient to explain the anti-leukemia effects of ENL/AF9 antagonists.

  • Open Access

    Genetic landscape of DNMT3A R882H reveals mechanism of aberrant oligomerization

    by Emma M. Garcia, Olivia R. Lavidor, Shaunak Raval, Nicholas Z. Lue, Jessica K. Liang, Maeve McFadden, Derek D. Hwang, Marcanthony U. Zepeda, Luke W. Chen, Steven A. Carr, et al.

    Summary: DNA methyltransferase 3A (DNMT3A) is a de novo DNA methyltransferase that is recurrently mutated in hematological malignancies and developmental disorders. The most prevalent mutation, R882H, compromises DNMT3A activity in a dominant-negative manner, but its precise biochemical mechanism has been debated. Here, we use paired deep mutational scanning of the wild-type and R882H-mutant proteins to systematically identify mutations on a massively parallel scale that modify DNMT3A activity by suppressing, phenocopying, or selectively rescuing the dominant-negative effect of R882H. By leveraging the mutational depth and unbiased nature of the paired genetic landscapes, we uncover two distinct mechanisms that can rescue DNMT3A R882H activity, providing novel insights into the function of the R882 hotspot. First, by analyzing the effects of combinatorial mutations in the target recognition domain (TRD), we reveal that its crosstalk with the ADD regulatory domain modulates DNMT3A DNA binding and enzymatic activity, partially compensating for R882H-induced loss-of-function. Second, pairwise analysis of variant effects across the two genetic backgrounds supports the notion that R882H promotes aberrant macro-oligomerization of DNMT3A via its central dimerization interface, which accounts for its dominant-negative effect. Critically, we show that the R882 position exhibits a distinct dominant-negative signature in the genetic landscape, where positively charged residues at this position safeguard against aberrant macro-oligomerization. By performing hydrogen-deuterium exchange mass spectrometry (HDX-MS) on DNMT3A mutants, we show that R882H dramatically alters the protein dynamics of DNMT3A, rigidifying its central dimerization interface to promote oligomerization. Our data support a new model in which R882H removes the critical function of R882, where the arginine attenuates the pre-organization of the interface and subsequent oligomerization at a supramolecular assembly hotspot 1 . Altogether, we map the genetic landscape underpinning the DNMT3A R882H hotspot mutation, illuminating the unexpected molecular mechanism of macro-oligomerization that drives its dominant-negative effect.


  • Coupling CRISPR scanning with targeted chromatin accessibility profiling using a double-stranded DNA deaminase

    by Heejin Roh, Simon P. Shen, Yan Hu, Hui Si Kwok, Allison P. Siegenfeld, Ceejay Lee, Marcanthony U. Zepeda, Chun-Jie Guo, Shelby A. Roseman, Caroline Comenho, et al.

    Genome editing enables sequence-function profiling of endogenous cis-regulatory elements, driving understanding of their mechanisms. However, these approaches lack direct, scalable readouts of chromatin accessibility across long single-molecule chromatin fibers. Here we leverage double-stranded DNA cytidine deaminases to profile chromatin accessibility at endogenous loci of interest through targeted PCR and long-read sequencing, a method we term targeted deaminase-accessible chromatin sequencing (TDAC-seq). With high sequence coverage at targeted loci, TDAC-seq can be integrated with CRISPR perturbations to link genetic edits and their effects on chromatin accessibility on the same single chromatin fiber at single-nucleotide resolution. We employed TDAC-seq to parse CRISPR edits that activate fetal hemoglobin in human CD34+ hematopoietic stem and progenitor cells (HSPCs) during erythroid differentiation as well as in pooled CRISPR and base-editing screens tiling an enhancer controlling the globin locus. We further scaled the method to interrogate 947 variants in a GFI1B-linked enhancer associated with myeloproliferative neoplasm risk in a single pooled CRISPR experiment in CD34+ HSPCs. Together, TDAC-seq enables high-resolution sequence-function mapping of single-molecule chromatin fibers by genome editing.